↑ トップへ　← 戻る

 Drug（薬物リスト） DrugBank | All Description Patterns💬 Info on mouse-over

e.g. Sirolimus, アダリムマブ

ABCDEFGH I JKLMNOPQRSTUVWXYZother

257 / 17,542 descriptions

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY
On map, Yellow: Drug target genes		 指定難病告示番号
1 2-(4-[5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy)-n-(methylsulfonyl)actamide - - - - 1件: 86 💬
2 90 mg hydrocortisone acetate suppository with sephure suppository applicator Acetate 2件: D00088, D00165 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 97 💬
3 A novel synthetic, orally-administered, non-peptide small molecule, which acts as - - - - 1件: 254 💬
4 A-dopamine Dopamine 2件: D00633, D07870 💬 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 1件:  6  💬
5 Abatacept active treatment Abatacept 1件: D03203 💬 2件: CD80, CD86 💬 12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 1件: 50 💬
6 Abatacept, rituximab or tocilizumab Abatacept 3件: D02596, D02994, D03203 💬 4件: CD80, CD86, IL6R, MS4A1 💬 24件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor 1件: 46 💬
7 Act - - - - 1件: 13 💬
8 Act - 064992 - - - - 1件: 86 💬
9 Act-050089 - - - - 1件: 86 💬
10 Act-050089 (ro 61-0612) - - - - 1件: 86 💬
11 Act-064992 - - - - 5件: 51, 85, 86, 88, 210 💬
12 Act-064992 (macitentan) Macitentan 1件: D10135 💬 2件: EDNRA, EDNRB 💬 9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 1件: 85 💬
13 Act-064992d - - - - 1件: 86 💬
14 Act-1 - - - - 1件: 13 💬
15 Act-128800 Ponesimod 1件: D11215 💬 1件: S1PR1 💬 3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 1件: 13 💬
16 Act-128800 dose 1 Ponesimod 1件: D11215 💬 1件: S1PR1 💬 3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 1件: 13 💬
17 Act-128800 dose 2 Ponesimod 1件: D11215 💬 1件: S1PR1 💬 3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 1件: 13 💬
18 Act-128800 dose 3 Ponesimod 1件: D11215 💬 1件: S1PR1 💬 3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 1件: 13 💬
19 Act-178418 - - - - 1件: 86 💬
20 Act-293987 - - - - 3件: 51, 86, 88 💬
21 Act-293987 (ns-304) - - - - 1件: 86 💬
22 Act-293987 / jnj-67896049 - - - - 1件: 84 💬
23 Act-334441 - - - - 1件: 49 💬
24 Act-385781a - - - - 1件: 86 💬
25 Act-385781a (actelion epoprostenol) Epoprostenol 2件: D00106, D01337 💬 1件: PTGIR 💬 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 1件: 86 💬
26 Act-434964 - - - - 1件: 19 💬
27 Actemra - - - - 2件: 46, 107 💬
28 Actemra(eu-licensed) - - - - 1件: 46 💬
29 Actemra, mra - - - - 1件: 107 💬
30 Acteoside Acteoside - - - 1件: 66 💬
31 Acth Corticotropin 1件: D00146 💬 1件: MC2R 💬 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 5件: 13, 66, 145, 193, 222 💬
32 Acth (acthar) gel Corticotropin 1件: D00146 💬 1件: MC2R 💬 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 1件: 66 💬
33 Acthar - - - - 9件:  2 , 13, 14, 46, 49, 50, 66, 84, 222 💬
34 Acthar 80 unit injection - - - - 1件: 66 💬
35 Acthar gel - - - - 6件: 13, 46, 49, 50, 84, 222 💬
36 Acthar gel (acth) Corticotropin 1件: D00146 💬 1件: MC2R 💬 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 1件: 13 💬
37 Acthar gel (adrenocorticotropic hormone) Corticotropin 1件: D00146 💬 1件: MC2R 💬 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 1件: 84 💬
38 Acthar gel 40 units twice weekly - - - - 1件: 84 💬
39 Acthar gel 80 units twice weekly. - - - - 1件: 84 💬
40 Acthar high dose (80 u) - - - - 1件: 49 💬
41 Acthar injectable product - - - - 1件: 46 💬
42 Acthar low dose (40 u) - - - - 1件: 49 💬
43 Acthrel - - - - 1件: 75 💬
44 Actimmune - - - - 1件: 326 💬
45 Actimmune registry - - - - 1件: 326 💬
46 Active bmn 111: daily subcutaneous injection of 15 ug/kg of bmn 111 - - - - 1件: 276 💬
47 Active comparator - - - - 2件:  6 , 46 💬
48 Active comparator receiving extavia® - - - - 1件: 13 💬
49 Active control - - - - 1件: 13 💬
50 Active drug (biib014) at 10, 30, 100, or 300 mg once daily. - - - - 1件:  6  💬
51 Active drug: pimavanserin 17mg (2 strength tablets) Pimavanserin - - - 1件:  6  💬
52 Active group - - - - 1件: 97 💬
53 Active investigational treatment ent-01 - - - - 1件:  6  💬
54 Active topical ns2 1% dermatologic cream - - - - 1件: 160 💬
55 Active treatment group 7% hypertonic saline - - - - 1件: 299 💬
56 Actonel 5mg film coated tablets - - - - 1件: 274 💬
57 Actonel once a week 35 mg film-coated tablets - - - - 1件: 274 💬
58 Actonel once a week 5mg film coated tablets - - - - 1件: 113 💬
59 Actonel/optinate 5mg film-coated tablets - - - - 1件: 274 💬
60 Actos (pioglitazone) Pioglitazone 2件: D00945, D08378 💬 1件: PPARG 💬 9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 1件: 13 💬
61 Actos 15 mg - - - - 1件:  2  💬
62 Actos 30 mg - - - - 1件:  2  💬
63 Actos 45 mg - - - - 1件:  2  💬
64 Actrapid 100 iu/ml, solution for injection in a vial - - - - 1件: 299 💬
65 Actrapid penfill 100ui/ml - - - - 1件: 299 💬
66 Actriia-igg1fc - - - - 1件: 86 💬
67 Adalimuab, etanercept, tocilizumab, or abatacept Abatacept 3件: D00742, D02596, D03203 💬 5件: CD80, CD86, IL6R, LTA, TNF 💬 77件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 1件: 46 💬
68 Adjuvant without active component - - - - 2件:  6 , 17 💬
69 Adrenocorticotrophic hormone acth Corticotropin 1件: D00146 💬 1件: MC2R 💬 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 1件: 222 💬
70 Adrenocorticotropic hormone (acth) gel (h.p. acthar®) Corticotropin 1件: D00146 💬 1件: MC2R 💬 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 1件: 13 💬
71 Anti baff (b cell activating factor) - - - - 1件: 49 💬
72 Antimicrobial therapy: co-trimoxazole or doxycycline Doxycycline 5件: D00307, D02129, D03903, D03904, D07876 💬 - - 1件: 85 💬
73 Anxiety/depression and work and activities - - - - 1件: 13 💬
74 Behavioral: bci-fit active querying - - - - 3件:  2 ,  6 , 17 💬
75 Behavioral: physical activity together for pwms and their cgs (pat-ms) - - - - 1件: 13 💬
76 Behavioral: role of dopamine Dopamine 2件: D00633, D07870 💬 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 1件:  6  💬
77 Biologically active human fecal microbiota - - - - 1件: 97 💬
78 Bromocriptine and other dopamine agonists Bromocriptine 4件: D00633, D00780, D03165, D07870 💬 6件: DRD1, DRD2, DRD3, DRD4, DRD5, PRL 💬 15件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway 1件:  6  💬
79 Bt-11 active - - - - 2件: 96, 97 💬
80 Cerebral dopamine neurotrophic factor Dopamine 2件: D00633, D07870 💬 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 1件:  6  💬
81 Cfz533 active - cohort 1 - - - - 1件: 53 💬
82 Cfz533 active - cohort 2 - - - - 1件: 53 💬
83 Cfz533 active - cohort 3 - - - - 1件: 53 💬
84 Cfz533 active -cohort 3 - - - - 1件: 53 💬
85 Cjnj-68150420-zzz-g001 (act- 064992d) - - - - 1件: 86 💬
86 Cjnj-68150420-zzz-g001 (act-064992d) - - - - 1件: 86 💬
87 Cjnj-68150420-zzz-g001(act-064992d) - - - - 1件: 86 💬
88 Combination oral budesonide and rectal hydrocortisone Budesonide 2件: D00088, D00246 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 97 💬
89 Combination product: active treatment with dual therapy - - - - 1件:  2  💬
90 Combination product: twice daily 90 mg hydrocortisone acetate suppository administered with sephure applicator Acetate 2件: D00088, D00165 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 97 💬
91 Continuous release dopamine agonists Dopamine 2件: D00633, D07870 💬 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 1件:  6  💬
92 Conventional glucocorticoids (immediate release hydrocortisone, cortisone acetate, prednisone, prednisolone, dexamethasone) Acetate 21件: D00088, D00292, D00472, D00473, D00973, D00975, D00980, D00981, D00982, D01239, D01510, D01615, D01632, D01948, D01998, D02156, D02174, D02591, D02592, D03301, D07749 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 81 💬
93 Cortef (hydrocortisone) Hydrocortisone 1件: D00088 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 83 💬
94 Corticoids+ tocilizumab 8mg/kg/4 weeks Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 41 💬
95 Corticotropin Corticotropin 1件: D00146 💬 1件: MC2R 💬 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 7件:  2 , 13, 46, 75, 78, 84, 222 💬
96 Corticotropin-releasing hormone Corticorelin 2件: D00146, D03905 💬 3件: CRHR1, CRHR2, MC2R 💬 6件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Long-term depression, Neuroactive ligand-receptor interaction, cAMP signaling pathway 1件: 75 💬
97 Decrease tocilizumab, abatacept Abatacept 2件: D02596, D03203 💬 3件: CD80, CD86, IL6R 💬 24件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor 1件: 46 💬
98 Device: actimyo recording - - - - 1件:  6  💬
99 Device: activated smart device - - - - 1件: 299 💬
100 Device: active stimulation - - - - 1件: 46 💬
101 Device: active tdcs - - - - 1件:  6  💬
102 Device: active tpcs - - - - 1件:  6  💬
103 Device: activity monitor Methamidophos - - - 1件: 113 💬
104 Device: de-activated smart device - - - - 1件: 299 💬
105 Device: nanocrystalline silver (acticoat) Silver - - - 2件: 35, 162 💬
106 Device: omnidirectional accelerometer monitor (3x3 cm and 16 g, actical®, philips respironics) Methamidophos - - - 1件: 118 💬
107 Device: wristband physical activity monitor Methamidophos - - - 1件: 13 💬
108 Diagnostic test: disease activity - - - - 1件: 46 💬
109 Diagnostic test: dm1-activc - - - - 1件: 113 💬
110 Diagnostic test: fibrinogen plasma concentration, coagulation factor xiii activity Factor XIII (human) - - - 1件: 288 💬
111 Dopamine Dopamine 2件: D00633, D07870 💬 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 3件:  6 ,  7 , 74 💬
112 Dopamine agent Dopamine 2件: D00633, D07870 💬 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 1件:  6  💬
113 Dopamine agonist treatment Dopamine 2件: D00633, D07870 💬 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 1件: 74 💬
114 Dopamine agonists Dopamine 2件: D00633, D07870 💬 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 1件: 74 💬
115 Dopamine agonists (pramipexole, ropirinole) Dopamine 4件: D00559, D00633, D05575, D07870 💬 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 1件:  6  💬
116 Doxycycline Doxycycline 5件: D00307, D02129, D03903, D03904, D07876 💬 - - 15件: 13, 23, 28, 46, 84, 85, 89, 96, 97, 158, 162, 167, 227, 280, 299 💬
117 Doxycycline 100 mg capsules Doxycycline 5件: D00307, D02129, D03903, D03904, D07876 💬 - - 1件: 89 💬
118 Doxycycline 100-200mg capsules daily for 6 months Doxycycline 5件: D00307, D02129, D03903, D03904, D07876 💬 - - 1件: 167 💬
119 Doxycycline hyclate Doxycycline 5件: D00307, D02129, D03903, D03904, D07876 💬 - - 3件: 23, 96, 227 💬
120 Doxycycline hyclate ph.eur Doxycycline 5件: D00307, D02129, D03903, D03904, D07876 💬 - - 1件: 167 💬
121 Doxycycline tablets Doxycycline 5件: D00307, D02129, D03903, D03904, D07876 💬 - - 1件: 46 💬
122 Dual release hydrocortisone (plenadren) Hydrocortisone 1件: D00088 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 81 💬
123 Efi/act-385781a - - - - 1件: 86 💬
124 Epoprostenol-actelion Epoprostenol 2件: D00106, D01337 💬 1件: PTGIR 💬 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 1件: 86 💬
125 Etanercepet, rituximab, abatacept, tocilizumab, sarilumab Abatacept 4件: D02596, D02994, D03203, D10161 💬 4件: CD80, CD86, IL6R, MS4A1 💬 24件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor 1件: 46 💬
126 Fentanyl Fentanyl 2件: D00320, D01399 💬 1件: OPRM1 💬 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 4件: 46, 70, 215, 231 💬
127 Fentanyl (high dose) Fentanyl 2件: D00320, D01399 💬 1件: OPRM1 💬 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 1件: 215 💬
128 Fentanyl (low dose) Fentanyl 2件: D00320, D01399 💬 1件: OPRM1 💬 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 1件: 215 💬
129 Fentanyl (low dose) + dexmedetomidine Dexmedetomidine 4件: D00320, D00514, D01205, D01399 💬 4件: ADRA2A, ADRA2B, ADRA2C, OPRM1 💬 4件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 1件: 215 💬
130 Fentanyl transdermal patch Fentanyl 2件: D00320, D01399 💬 1件: OPRM1 💬 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 1件: 46 💬
131 Gene activated human glucocerebrosidase - - - - 1件: 19 💬
132 Gene activated human glucocerebrosidase, velaglucerase alfa Velaglucerase alfa 1件: D09029 💬 1件: GBA 💬 4件: Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 1件: 19 💬
133 Gene-activated human glucocerebrosidase - - - - 1件: 19 💬
134 Gene-activated human glucocerebrosidase 200u/vial - - - - 1件: 19 💬
135 Gene-activated human glucocerebrosidase 400u/vial - - - - 1件: 19 💬
136 H.p. acthar gel - - - - 5件: 46, 49, 50, 84, 222 💬
137 H.p. acthar gel (repository corticotropin injection) Corticotropin 1件: D00146 💬 1件: MC2R 💬 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 1件: 13 💬
138 H.p. acthar® gel - - - - 1件: 14 💬
139 Hril-2 active - - - - 3件: 46, 49, 53 💬
140 Hydrocortisone Hydrocortisone 1件: D00088 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 9件:  6 , 46, 53, 75, 78, 81, 83, 97, 299 💬
141 Hydrocortisone (solucortef) Hydrocortisone 1件: D00088 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 81 💬
142 Hydrocortisone 100mg/ml Hydrocortisone 1件: D00088 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 83 💬
143 Hydrocortisone 10mg Hydrocortisone 1件: D00088 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 46 💬
144 Hydrocortisone 10mg tablet Hydrocortisone 1件: D00088 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 81 💬
145 Hydrocortisone 10mg tablets Hydrocortisone 1件: D00088 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 81 💬
146 Hydrocortisone 20mg tablets Hydrocortisone 1件: D00088 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 81 💬
147 Hydrocortisone acetate Acetate 2件: D00088, D00165 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 97 💬
148 Hydrocortisone cream Hydrocortisone 1件: D00088 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件:  6  💬
149 Hydrocortisone cream 1% Hydrocortisone 1件: D00088 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件:  6  💬
150 Hydrocortisone cream 10mg/g fna fagron Hydrocortisone 1件: D00088 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件:  6  💬
151 Hydrocortisone hydrogen succinate Hydrocortisone 2件: D00088, D01442 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 83 💬
152 Hydrocortisone modified release capsules Hydrocortisone 1件: D00088 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 81 💬
153 Hydrocortisone roussel Hydrocortisone 1件: D00088 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 83 💬
154 Hydrocortisone sodium acetate Acetate 2件: D00088, D01779 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 81 💬
155 Hydrocortisone sodium phosphate Hydrocortisone 1件: D00088 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 3件: 53, 81, 83 💬
156 Hydrocortisone sodium succinate Hydrocortisone 1件: D00088 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 3件: 81, 83, 97 💬
157 Hydrocortisone tablet 2.5 mg Hydrocortisone 1件: D00088 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 81 💬
158 Hydrocortisone takeda, tabletter Hydrocortisone 1件: D00088 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 78 💬
159 Inn-tocilizumab Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 266 💬
160 Interferon beta 1a, oral doxycycline Doxycycline 6件: D00307, D02129, D03903, D03904, D04554, D07876 💬 2件: IFNAR1, IFNAR2 💬 18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 1件: 13 💬
161 Interferon gamma-1b Interferon Gamma 1件: D00747 💬 2件: IFNGR1, IFNGR2 💬 18件: Chagas disease, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis 7件: 18, 65, 85, 228, 299, 301, 326 💬
162 Interferon gamma-1b (actimmune) Interferon Gamma 1件: D00747 💬 2件: IFNGR1, IFNGR2 💬 18件: Chagas disease, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis 1件: 85 💬
163 Intra-articular tocilizumab Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 46 💬
164 Jnj-67896049 (act-293987) - - - - 1件: 86 💬
165 Jnj-67896062 / act-064992 - - - - 2件: 86, 88 💬
166 Lamotrigin actavis - - - - 1件: 114 💬
167 Long-acting somatostatin Somatostatin 1件: D07431 💬 5件: SSTR1, SSTR2, SSTR3, SSTR4, SSTR5 💬 4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 1件: 67 💬
168 Macitentan (act-064992) Macitentan 1件: D10135 💬 2件: EDNRA, EDNRB 💬 9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 1件: 86 💬
169 Mesalazine with hydrocortisone sodium succinate Hydrocortisone 2件: D00088, D00377 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 97 💬
170 Mra (actemra) - - - - 1件: 107 💬
171 Mra (tocilizumab) Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 2件: 46, 107 💬
172 Mra(tocilizumab) Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 2件: 46, 107 💬
173 Mra, actemra - - - - 2件: 46, 107 💬
174 Multi-modal pain management [fentanyl] Fentanyl 2件: D00320, D01399 💬 1件: OPRM1 💬 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 1件: 70 💬
175 Novorapid / humalog short acting insulin - - - - 1件: 299 💬
176 Octreotide lar / sandostatin lar (lar=long acting release) Octreotide 2件: D00442, D06495 💬 1件: SSTR2 💬 4件: Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 1件: 84 💬
177 Other: corticotropin releasing hormone (crh) Corticotropin 1件: D00146 💬 1件: MC2R 💬 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 1件: 78 💬
178 Other: fitbit activity monitor Methamidophos - - - 1件: 49 💬
179 Other: hydrocortisone Hydrocortisone 1件: D00088 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 75 💬
180 Other: low dose (1 mcg) acth stimulation test Corticotropin 1件: D00146 💬 1件: MC2R 💬 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 1件: 193 💬
181 Other: no active treatment - - - - 1件: 274 💬
182 Other: no doxycycline Doxycycline 5件: D00307, D02129, D03903, D03904, D07876 💬 - - 1件: 299 💬
183 Other: noninvasive actigraphy monitor Methamidophos - - - 1件: 86 💬
184 Other: tampa kinesiophobia scale, berg-balance test, international physical activity questionnaire-short form, falls efficacy scale Isoxaflutole - - - 1件:  6  💬
185 Ovine corticotropin-releasing hormone (ocrh) Corticorelin 2件: D00146, D03905 💬 3件: CRHR1, CRHR2, MC2R 💬 6件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Long-term depression, Neuroactive ligand-receptor interaction, cAMP signaling pathway 1件: 75 💬
186 Pioglitazone Pioglitazone 2件: D00945, D08378 💬 1件: PPARG 💬 9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 17件:  2 ,  6 , 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 💬
187 Pioglitazone 15 mg Pioglitazone 2件: D00945, D08378 💬 1件: PPARG 💬 9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 1件: 96 💬
188 Pioglitazone and tretinoin Pioglitazone 3件: D00094, D00945, D08378 💬 4件: PML, PPARG, RARA, RARB 💬 19件: AMPK signaling pathway, Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Huntington disease, Influenza A, Longevity regulating pathway, Non-small cell lung cancer, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 1件:  2  💬
189 Pioglitazone or metformin Metformin 4件: D00944, D00945, D04966, D08378 💬 3件: PPARG, PRKAA1, PRKAA2 💬 25件: AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Huntington disease, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Osteoclast differentiation, Oxytocin signaling pathway, PI3K-Akt signaling pathway, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Tight junction, Transcriptional misregulation in cancer, mTOR signaling pathway 1件: 265 💬
190 Procedure: embryonic dopamine cell implant surgery Dopamine 2件: D00633, D07870 💬 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 1件:  6  💬
191 Procedure: hydrocortisone withdrawal Hydrocortisone 1件: D00088 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 81 💬
192 Recombinant human cerebral dopamine neurotrophic factor Dopamine 2件: D00633, D07870 💬 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 1件:  6  💬
193 Reh-acteoside Acteoside - - - 1件: 66 💬
194 Repository corticotropin injection Corticotropin 1件: D00146 💬 1件: MC2R 💬 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 5件:  2 , 13, 46, 84, 222 💬
195 Repository corticotropin injection -treatment extension Corticotropin 1件: D00146 💬 1件: MC2R 💬 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 1件: 84 💬
196 Risedronate sodium (actonel) Risedronic acid 3件: D00942, D03234, D08484 💬 1件: FDPS 💬 4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 1件: 274 💬
197 Risedronic acid Risedronic acid 3件: D00942, D03234, D08484 💬 1件: FDPS 💬 4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 3件: 93, 95, 274 💬
198 Rituximab, observational study amon patients with active ra Rituximab 1件: D02994 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 1件: 46 💬
199 Ro 47-0203 / act-050088 - - - - 1件: 86 💬
200 Ro actemra - - - - 1件: 46 💬
201 Ro-actemra - - - - 1件: 46 💬
202 Ro47-0203 / act-050088 - - - - 2件: 51, 86 💬
203 Sar156597 (act14604) - - - - 1件: 51 💬
204 Selexipag, act-293987 (ns-304) Selexipag 1件: D09994 💬 1件: PTGIR 💬 3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 1件: 86 💬
205 Short-acting insulin (actrapid) - - - - 1件: 299 💬
206 Solu-cortef (hydrocortisone) Hydrocortisone 1件: D00088 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 83 💬
207 Solu-cortef, powder for solution for injection, 100mg, and 'act-o-vial' - - - - 1件:  6  💬
208 Standard analgesia use [fentanyl] Fentanyl 2件: D00320, D01399 💬 1件: OPRM1 💬 3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 1件: 70 💬
209 Subcutaneous hydrocortisone Hydrocortisone 1件: D00088 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 81 💬
210 Subcutaneous hydrocortisone 10mg Hydrocortisone 1件: D00088 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件:  6  💬
211 Subcutaneous tocilizumab Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 46 💬
212 Time and attention + active fructooligosaccharide supplementation - - - - 1件: 96 💬
213 Tocilizumab Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 18件:  2 , 13, 40, 41, 42, 43, 46, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬
214 Tocilizumab (actemra or roactemra) Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 46 💬
215 Tocilizumab (actemra) Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 46 💬
216 Tocilizumab (actemra®) Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 46 💬
217 Tocilizumab (mra-sc) Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 40 💬
218 Tocilizumab (tcz) Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 2件: 46, 56 💬
219 Tocilizumab + glucocorticoids (gcs) Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 41 💬
220 Tocilizumab + methotrexate(mtx) Methotrexate 3件: D00142, D02115, D02596 💬 3件: DHFR, DHFR2, IL6R 💬 17件: Antifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 46 💬
221 Tocilizumab 162 mg Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 46 💬
222 Tocilizumab 162mg/0.9ml jeringa sc Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 46 💬
223 Tocilizumab 162mg/0.9ml sc pfs sc Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 46 💬
224 Tocilizumab 162mg/0.9ml syringe sc Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 46 💬
225 Tocilizumab [roactemra/actemra] Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 4件: 46, 51, 107, 331 💬
226 Tocilizumab [roactemra] Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 46 💬
227 Tocilizumab and iv steroids combination Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 41 💬
228 Tocilizumab infusion roacemtra (eu) Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 266 💬
229 Tocilizumab injection Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 13 💬
230 Tocilizumab iv Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 46 💬
231 Tocilizumab plus methotrexate Methotrexate 3件: D00142, D02115, D02596 💬 3件: DHFR, DHFR2, IL6R 💬 17件: Antifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 46 💬
232 Tocilizumab prefilled syringe Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 46 💬
233 Tocilizumab roche Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 2件: 46, 107 💬
234 Tocilizumab sc Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 3件: 41, 46, 107 💬
235 Tocilizumab sc 162 mg/0.9 ml disposable auto-injector (ai) Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 46 💬
236 Tocilizumab sc 162 mg/0.9 ml pre-filled syringe with safety device (pfs) Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 46 💬
237 Tocilizumab sc 162 mg/0.9 ml prefilled syringe with safety device (pfs) Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 51 💬
238 Tocilizumab treatment Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 41 💬
239 Tocilizumab+methotrexate(mtx) Methotrexate 3件: D00142, D02115, D02596 💬 3件: DHFR, DHFR2, IL6R 💬 17件: Antifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 46 💬
240 Tocilizumab, abatacept Abatacept 2件: D02596, D03203 💬 3件: CD80, CD86, IL6R 💬 24件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor 1件: 46 💬
241 Transdermal fentanyl matrix, gabapentin Fentanyl 3件: D00320, D00332, D01399 💬 6件: CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, OPRM1, SLC6A1 💬 12件: Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, Estrogen signaling pathway, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, Synaptic vesicle cycle 1件: 70 💬
242 Treatment defined only by active substance - - - - 1件: 50 💬
243 Treatment with systemic therapy (doxycycline) Doxycycline 5件: D00307, D02129, D03903, D03904, D07876 💬 - - 1件: 162 💬
244 Tretinoin and pioglitazone hcl Pioglitazone 3件: D00094, D00945, D08378 💬 4件: PML, PPARG, RARA, RARB 💬 19件: AMPK signaling pathway, Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Huntington disease, Influenza A, Longevity regulating pathway, Non-small cell lung cancer, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 1件:  2  💬
245 Udca (ursodeoxycholic acid) Ursodeoxycholic acid 1件: D00734 💬 1件: NR1H4 💬 1件: Bile secretion 1件: 93 💬
246 Ursodeoxycholic acid Ursodeoxycholic acid 1件: D00734 💬 1件: NR1H4 💬 1件: Bile secretion 8件:  6 , 67, 84, 93, 94, 95, 96, 97 💬
247 Ursodeoxycholic acid (udca) Ursodeoxycholic acid 1件: D00734 💬 1件: NR1H4 💬 1件: Bile secretion 1件: 94 💬
248 Ursodeoxycholic acid (urso) Ursodeoxycholic acid 1件: D00734 💬 1件: NR1H4 💬 1件: Bile secretion 1件: 93 💬
249 Ursodeoxycholic acid 300mg capsule Ursodeoxycholic acid 1件: D00734 💬 1件: NR1H4 💬 1件: Bile secretion 1件: 93 💬
250 Ursodeoxycholic acid 300mg tablet Ursodeoxycholic acid 1件: D00734 💬 1件: NR1H4 💬 1件: Bile secretion 1件: 93 💬
251 Ursodeoxycholic acid capsules Ursodeoxycholic acid 1件: D00734 💬 1件: NR1H4 💬 1件: Bile secretion 1件: 93 💬
252 Ursodeoxycholic acid combination of immunosuppressive agents Ursodeoxycholic acid 1件: D00734 💬 1件: NR1H4 💬 1件: Bile secretion 2件: 93, 95 💬
253 Ursodeoxycholic acid combined with total glucosides of paeony Ursodeoxycholic acid 1件: D00734 💬 1件: NR1H4 💬 1件: Bile secretion 1件: 93 💬
254 Ursodeoxycholic acid only Ursodeoxycholic acid 1件: D00734 💬 1件: NR1H4 💬 1件: Bile secretion 1件: 93 💬
255 Ursodeoxycholic acid+low dose glucocorticoid(prednisone) Prednisone 2件: D00473, D00734 💬 2件: NR1H4, NR3C1 💬 2件: Bile secretion, Neuroactive ligand-receptor interaction 1件: 93 💬
256 Ursodiol (ursodeoxycholic acid, udca) Ursodeoxycholic acid 1件: D00734 💬 1件: NR1H4 💬 1件: Bile secretion 1件: 97 💬
257 Uttr1147a/ro7021610 (active) - - - - 2件: 96, 97 💬

先頭へ